Cetuximab for treatment of advanced squamous cell carcinoma in solid organ transplant recipients

Wiener Medizinische Wochenschrift

Volumn 163, Issue 15-16, 2013, Pages 372-375

  Boyd, Katherine ^a,b   Shea, Sofia M ^a,b   Patterson, James ^a,b  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Cetuximab; Epidermal growth factor (EGF) receptor; Organ transplant patients; Squamous cell carcinoma

Indexed keywords

CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; ETRETIN; FLUOROURACIL; IMIQUIMOD; LIQUID NITROGEN; PACLITAXEL; RETINOID;

ACNE; ADJUVANT THERAPY; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RADIOTHERAPY; COLORECTAL CARCINOMA; CURETTAGE; DIARRHEA; DRUG ERUPTION; EXCISION; GRAFT RECIPIENT; HEAD AND NECK CARCINOMA; HEART TRANSPLANTATION; HUMAN; HYPERPIGMENTATION; HYPERSENSITIVITY; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LUNG NON SMALL CELL CANCER; MONOTHERAPY; MUCOSA INFLAMMATION; NON MELANOMA SKIN CANCER; ORGAN TRANSPLANTATION; PANCREAS CANCER; PARONYCHIA; PHOTODYNAMIC THERAPY; SEPSIS; SIDE EFFECT; SKIN MANIFESTATION; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; TRICHOMEGALY; XEROSIS;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; NEOPLASM STAGING; NEOPLASMS, MULTIPLE PRIMARY; ORGAN TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; RISK FACTORS; SKIN NEOPLASMS;

EID: 84885176471     PISSN: 00435341     EISSN: 1563258X     Source Type: Journal    
DOI: 10.1007/s10354-013-0213-5     Document Type: Article

References (22)

1. Jensen P, Hansen S, Moller B, Leivestad T, et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol. 1999;40:177-86.
2. Ritchie SA, Patel MJ Miller SJ. Therapeutic options to decrease actinic keratosis and squamous cell carcinoma incidence and progression in solid organ transplant recipients: a practical approach. Dermatol Surg. 2012;38:1604-21.
3. Guthrie TH Jr, Porubsky ES, Luxenberg MN, Shah KJ, Wurtz KL, Watson PR. Cisplatin-based chemotherapy in advanced basal and squamous cell carcinomas of the skin: results in 28 patients including 13 patients receiving multimodality therapy. J Clin Oncol. 1990;8:342-6.
4. Martinez JC, Otley CC, Okuno SH, Foote RL, Kasperbauer JL. Chemotherapy in the setting of advanced cutaneous squamous cell carcinoma in organ transplant recipients: theoretical and practical considerations. Dermatol Surg. 2004;30:679-86.
5. Ch'ng S, Low I, Ng D, et al. Epidermal growth factor receptor: a novel biomarker for aggressive head and neck cutaneous squamous cell carcinoma. Hum Pathol. 2008;39:344-9.
6. Cranmer LD, Engelhardt C, Morgan SS. Treatment of unresectable and metastatic cutaneous squamous cell carcinoma. Oncologist. 2010;15:1320-8.
7. Preneau S, Rio E, Brocard A, Peuvrel L, Nguyen JM, Quereux G, Dreno B. Efficacy of cetuximab in the treatment of squamous cell carcinoma. J Dermatolog Treat. 2013;1-4 (Epub ahead of print).
8. Kies MS, Holsinger FC, Lee JJ, William WN Jr, Glisson BS, Lin HY, et al. Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial. J Clin Oncol. 2010;28:8-14.
9. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-47.
10. Maubec E, Petrow P, Duvillard P, et al. Cetuximab as first-line monotherapy in patients with skin unresectable squamous cell carcinoma: final results of a phase II multicenter study (abstract). J Clin Oncol. 2010;28:8510.
11. Kalapurakal SJ, Malone J, Robbins KT, Buescher L, Godwin J, Rao K. Cetuximab in refractory skin cancer treatment. J Cancer. 2012;3:257-61.
12. Bauman JE, Eaton KD, Martins RG. Treatment of recurrent squamous cell carcinoma of the skin with cetuximab. Arch Dermatol. 2007;143:889-92.
13. Suen JK, Bressler L, Hord SS, et al. Cutaneous squamous cell carcinoma responding serially to single-agent cetuximab. Anticancer Drugs. 2007;18:827-92.
14. Wollina U. Cetuximab in non-melanoma skin cancer. Expert Opin Biol Ther. 2012 Jul;12(7):949-56.
15. Giacchero D, Barriere J, Benezery K, Guillot B, Dutriaux C, Mortier L, Lacour J-P, Thuss A, Peyrade F. Efficacy of cetuximab for unresectable or advanced cutaneous squamous cell carcinoma - a report of eight cases. Clin Oncol. 2011;23:716-21.
16. Mecca C, Ponzetti A, Caliendo V, Ciuffreda L, Lista P. Complete response of metastatic cutaneous squamous cell carcinoma to cetuximab plus paclitaxel. Eur J Dermatol. 2012;22(6):758-61.
17. Vaccaro M, Barbuzza O, Pollicino A, Guarneri C. Acneiform eruption following molecular targeted chemotherapy. Intern Med J. 2011 Apr;41(4):361-2.
18. Harding J, Burtness B. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody. Durgs Today 2005;41(2)107-27.
19. Valeriani M, Muni R, Osti MF, De Sanctis V, Minniti G, Ardito F, Maurizi Enrici R. Acute toxicity in 14 patients with locally advanced head and neck squamous cell carcinoma treated with concurrent cetuximab and radiotherapy. Radio Med. 2012;117:125-32.
20. Bonner JA, Harai PM, Girait J et al. Radiotherapy plus cetuximab for squamous cell carcinoma of the head and neck. N Engl J Med. 2006;354:567-78.
21. Mydin AR, Armstrong JG. Radiotherapy plus cetuximab is safe in a head and neck cancer patient on immunosuppressants for liver transplant. J Clin Oncol 2007 Feb;365-6.
22. Leard LE, Cho BK, Jones KD, Hays SR, Tope WD, Golden JA, Hoopes CW. Fatal diffuse alveolar damage in two lung transplant patients treated with cetuximab. J Heart Lung Transplant. 2007;26:1340-4.